



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 49/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/08714</b> <b>(43) International Publication Date:</b> 25 February 1999 (25.02.99)
<b>(21) International Application Number:</b> PCT/GB98/02481 <b>(22) International Filing Date:</b> 19 August 1998 (19.08.98) <b>(30) Priority Data:</b> 9717588.9                      19 August 1997 (19.08.97)                      GB <b>(71) Applicant (for GB only):</b> MARSDEN, John, Christopher [GB/GB]; Frank B. Dehn & Co., 179 Queen Victoria Street, London EC4V 4EL (GB). <b>(71) Applicant (for all designated States except US):</b> NYCOMED IMAGING AS [NO/NO]; Nycoveien 2, P.O. Box 4220 Torshov, N-0401 Oslo 4 (NO). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> ØSTENSEN, Jonny [NO/NO]; Nycomed Imaging AS, Nycoveien 2, P.O. Box 4220 Torshov, N-0401 Oslo 4 (NO). ERIKSEN, Morten [NO/NO]; Nycomed Imaging AS, Nycoveien 2, P.O. Box 4220 Torshov, N-0401 Oslo 4 (NO). TORNES, Audun [NO/NO]; Nycomed Imaging AS, Nycoveien 2, P.O. Box 4220 Torshov, N-0401 Oslo 4 (NO). FRIGSTAD, Sigmund [NO/NO]; Frode Rinnans Vei 68, N-7035 Trondheim (NO).		<b>(74) Agents:</b> MARSDEN, John, Christopher et al.; Frank B. Dehn & Co., 179 Queen Victoria Street, London EC4V 4EL (GB).  <b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
<b>(54) Title:</b> IMPROVEMENTS IN OR RELATING TO CONTRAST AGENTS  <b>(57) Abstract</b> <p>Ultrasound imaging using gas microbubble-containing contrast agents may be performed in the recirculating phase following admixture of the contrast agent with the blood pool, thereby prolonging the useful imaging time window compared to that conventionally obtained during the backscatter signal peak resulting from first pass of a contrast agent bolus. The length of the time window may further be increased by imaging at ultrasound frequencies of 2 MHz or less, particularly by harmonic imaging at transmit frequencies less than the resonance frequencies of the gas microbubbles.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

- 1 -

66964002.601

Improvements in or relating to contrast agents

5           This invention relates to gas-containing ultrasound contrast agents, more particularly to their use in diagnostic ultrasound imaging.

10           It is well known that ultrasonic imaging comprises a potentially valuable diagnostic tool, for example in studies of the vascular system, particularly in  
cardiography, and of tissue microvasculature. A variety of contrast agents has been proposed to enhance the  
acoustic images so obtained, including suspensions of  
solid particles, emulsified liquid droplets, gas  
15   microbubbles and encapsulated gases or liquids. It is generally accepted that low density contrast agents which are easily compressible are particularly efficient in terms of the acoustic backscatter they generate, and considerable interest has therefore been shown in the  
20   preparation of gas-containing and gas-generating systems.

          Initial studies involving free gas microbubbles generated *in vivo* by intracardiac injection of physiologically acceptable substances have demonstrated  
25   the potential efficiency of such microbubbles as contrast agents in echography; such techniques are severely limited in practice, however, by the short lifetime of the free microbubbles. Substantial interest has accordingly been shown in methods of stabilising gas  
30   bubbles for echocardiography and other ultrasonic studies, for example using emulsifiers, oils, thickeners or sugars, or by entraining or encapsulating the gas or a precursor therefor in a variety of systems, e.g. as porous gas-containing microparticles or as encapsulated  
35   gas microbubbles, and in the selection of gases which may themselves exhibit enhanced stability and duration of echogenic effect.

          Prior art concerning both the use of phospholipids

- 2 -

as components of gas-containing ultrasound contrast agents and the selection of gases said to give improved persistence *in vivo* is reviewed in WO-A-9729783, the contents of which are incorporated herein by reference.

5 WO-A-9729783 itself discloses contrast agents for use in diagnostic studies comprising a suspension in an injectable aqueous carrier liquid of gas microbubbles stabilised by phospholipid-containing amphiphilic material, characterised in that the amphiphilic material  
10 consists essentially of phospholipid predominantly comprising molecules with net charges. The phospholipid molecules are preferably negatively charged, for example as in naturally occurring (e.g. soya bean or egg yolk derived), semisynthetic (e.g. partially or fully  
15 hydrogenated) and synthetic phosphatidylserines, phosphatidylglycerols, phosphatidylinositols, phosphatidic acids and cardiolipins.

Contrast agents in which at least 70% of the phospholipid content consists of one or more  
20 phosphatidylserines, for example saturated (e.g. hydrogenated or synthetic) natural phosphatidylserine and synthetic or semi-synthetic dialkanoylphosphatidylserines such as distearoylphosphatidylserine, dipalmitoylphosphatidylserine and diarachidoyl-  
25 phosphatidylserine, are said to be preferred by virtue of their stability, minimal haemodynamic side effects and ease of elimination from the body.

Gases which may be present in such contrast agents include any substances (including mixtures)  
30 substantially or completely in gaseous (including vapour) form at the normal human body temperature of 37°C. Representative gases thus include air, nitrogen, oxygen, carbon dioxide, hydrogen, nitrous oxide, inert gases, sulphur fluorides, hydrocarbons and halogenated  
35 hydrocarbons, especially fluorocarbons such as perfluorocarbons, typically containing 1-5 carbon atoms. The use of fluorinated gases such as sulphur hexafluoride, perfluoroalkanes and perfluorocycloalkanes

- 3 -

is particularly preferred.

Ultrasound contrast agents are usually administered intravenously as a single bolus dosage, leading to a rapid and pronounced but relatively short lasting rise in backscatter intensity in respect of blood-perfused tissue and organs as the bolus mixes with surrounding blood, thereby generating a relatively narrow and high intensity backscatter signal peak in a plot against time; backscatter measurements are normally made during the existence of this peak. This may, however, give rise to problems in, for example, the imaging of deeper tissues and organs, where high backscatter from overlying tissue during the peak period may cause excessive shadowing.

It is often desirable to prolong the useful time window for imaging beyond the relatively short duration of the backscatter signal peak resulting from passage of the contrast agent bolus. In the case of non-recirculating contrast agents, i.e. agents which are incapable of surviving more than one passage through the systemic circulation, for example as a result of instability or of specific or non-specific trapping in certain tissues, this may require repeated injection or continuous infusion of the contrast agent; however, such techniques may be inconvenient in practice and may require special pharmaceutical formulations. Use of increased dosages of non-recirculating contrast agents in an attempt to prolong the imaging time window may be limited by toxicity considerations and will frequently cause excessive acoustic shadowing, thereby significantly shortening the useful time window.

Stabilised gas microbubble-containing contrast agents such as those disclosed in WO-A-9729783 are capable of surviving passage through the systemic circulation. Such agents can pass through the pulmonary capillary bed and survive the systolic pressure changes encountered in the blood stream, and so may provide measurable backscatter levels after mixture with the

- 4 -

whole blood pool. In such cases a plot of backscatter intensity against time will exhibit a decay phase after the peak period as a result of the presence of echogenic contrast agent in recirculating blood; this is  
5 hereinafter referred to as the "recirculating phase".  
Hitherto, measurements of backscatter intensity during the recirculating phase have generally been disregarded, probably because of the low intensity levels involved. It has now surprisingly been found, however, that  
10 imaging during the recirculating phase may provide diagnostically useful results over a prolonged time period if a sufficient dosage of contrast agent is administered.

Thus the present invention is based on the finding  
15 that increasing the dose of a recirculating ultrasound contrast agent may lead to a substantial and disproportionately large increase in the useful imaging time window. Without wishing to be bound by theoretical considerations, it is thought that this unexpectedly  
20 prolonged time window may be the result of a change in the mechanism governing contrast duration. Thus, at low doses, contrast duration is determined solely by the bolus transit time, which is governed by the relationship between central blood volume and cardiac  
25 output. At high doses, on the other hand, contrast duration depends on clearance of the contrast agent from the blood, for example on the relationship between total blood volume and hepatic blood flow in the case of a contrast agent with predominantly hepatic clearance.

30 Thus according to one aspect of the invention there is provided a method of ultrasound imaging which comprises (i) administering an ultrasound contrast agent comprising a stabilised dispersion of gas microbubbles in an injectable carrier liquid to the vascular system  
35 of a subject in an amount which is physiologically tolerable and sufficient to generate contrast enhancement within blood in a recirculating phase following admixture of the agent with the blood pool;

- 5 -

and (ii) generating an ultrasound image of at least a part of the vascular system of said subject during said recirculating phase.

In a further embodiment the invention provides use of stabilised gas microbubbles in the manufacture of a contrast agent for administration to the vascular system of a subject in a dosage unit which is physiologically tolerable and sufficient to generate contrast enhancement within blood in a recirculating phase following admixture of the agent with the blood pool.

The contrast agents may, for example, comprise amphiphile-stabilised, e.g. phospholipid-stabilised, gas microbubbles, advantageously in which the phospholipids or other amphiphiles form monolayer membranes at the microbubble-carrier liquid interfaces; such agents may combine high efficacy and low toxicity by virtue of the flexibility and low material content of the stabilising membranes. The use of negatively charged phospholipids as described in WO-A-9729783 is preferred, the use of phosphatidylserines, e.g. to stabilise fluorinated gases such as perfluorobutane, being particularly preferred since the particularly low toxicity of such products facilitates their use at higher dosages.

Such contrast agents may, for example, be administered at up to 30, e.g. 5-15 times the dosage which might normally be employed for conventional imaging of tissue such as the myocardium during the peak concentration period. Thus in the case of harmonic imaging using contrast agents as described in WO-A-9729783, contrast agent doses such that the amount of phospholipid injected is in the range 2-10  $\mu\text{g/kg}$  may be useful. The agents may, for example, be administered as a plurality of small doses in sequence, as a continuous infusion over an appropriate period of time or as a single high dose; this last method will generally be preferred for simplicity and convenience.

It will be appreciated that, for any given contrast agent, there will be an upper dosage limit above which

- 6 -

shadowing will dominate for a dosage-dependent period of time, whereafter the useful imaging time window will begin; the length of the time window will remain constant at any dosage above this upper limit. The optimum dosage will therefore be one which gives substantial prolongation of the time window without causing shadowing in the recirculating phase.

Whereas imaging during the peak concentration period is typically constrained to an imaging time window of at most 4 minutes, sometimes less than 1 minute, imaging in the recirculating phase in accordance with the present procedure of tissue such as the myocardium may give an imaging time window in excess of 10, 15, 30 or even 45 minutes.

The useful imaging time window effectively ends when the backscatter from contrast agent in the recirculating phase falls to the tissue baseline level. It is therefore advantageous to use harmonic imaging techniques such as second harmonic imaging in the method of the invention, since these suppress tissue echo relative to contrast echo and will therefore extend the imaging time window. Thus, for example, a relative suppression of tissue echo by 10 dB will prolong the effective imaging time by about 3 halftimes, since  $0.1 \approx (0.5)^3$ .

It has also been found that imaging time windows, particularly for deeply located tissue sites, may be lengthened by use of lower than usual ultrasound imaging frequencies. It is well known that increased ultrasound frequency leads to enhanced image resolution but also results in higher attenuation; it is accordingly necessary to compromise in order to balance the requirements of adequate resolution and tissue penetration. Current diagnostic ultrasound imaging procedures typically employ frequencies of 2-10 MHz for transcutaneous measurements; thus, for example, frequencies of 2.5-5 MHz, e.g. 3.5 MHz, are commonly employed in adult cardiology and deep organ imaging.



- 7 -

Where highly echogenic gas microbubble-containing contrast agents are used, imaging of deeply located tissue sites of interest may be hindered as a result of attenuation (and therefore shadowing) by contrast agent in overlying tissue. Imaging of tissue in the region of interest will thus not be practicable until such attenuation has fallen sufficiently for backscatter from the tissue of interest to be determinable, thereby delaying onset of the time window for useful observations. This time window will then last until backscatter from the tissue of interest falls below the minimum level for useful observations.

The use of lower imaging frequencies, e.g. 2 MHz or less, may lengthen the imaging time window by reducing or even eliminating attenuation by contrast agent in overlying tissue and possibly also by such tissue itself, thereby advancing the time from which useful observations of the underlying tissue of interest may be made.

The imaging frequency may, for example, be in the range 1-2 MHz, and may advantageously be less than 1.8 MHz, preferably less than 1.6 MHz, for example about 1.5 MHz. The use of harmonic imaging techniques, for example second harmonic imaging, and analogous techniques such as pulse inversion imaging, may be particularly advantageous; in such cases the above-defined frequencies refer to the transmitted ultrasound signals.

It will be appreciated that such transmit frequencies are significantly below the resonance frequencies of most gas microbubble-containing contrast agents, these typically being of the order of 3-5 MHz. It has hitherto been a general belief that non-linear imaging techniques such as harmonic imaging require oscillation of microbubbles at their resonance frequency (see, for example, *Ultrasonics 15(1)*, pp. 7-13 (1977)), so that deviation from the resonance frequency is generally considered to be disadvantageous. The finding

- 8 -

that harmonic imaging at a transmit frequency below the resonance frequency of the microbubbles produces improved contrast to tissue signal ratios and thus substantially prolongs the useful imaging time window is therefore most unexpected.

Without wishing to be bound by theoretical considerations, it is believed that non-linear imaging such as second harmonic imaging does not in fact require the phenomenon of microbubble resonance. Thus, provided that a sufficient oscillation amplitude is experienced at the transmit frequency, non-linear oscillations may be the main source of harmonic components in the contrast obtained from contrast agent microbubbles, although not at the optimum level corresponding to resonance frequencies.

The use of lower transmit frequencies is advantageous in that attenuation is thereby reduced, allowing more power to penetrate and reach the region of interest and so giving more efficient harmonic conversion. Since, as noted above, shadowing is reduced by the use of lower frequencies, the maximum useful dose of contrast agent may be increased, thereby permitting further lengthening of the useful imaging time window.

This embodiment of the invention is particularly suited to perfusion imaging, for example myocardial perfusion imaging. It will be appreciated that spatial resolution, which may to some extent be compromised by the use of low imaging frequencies, may not be a critical parameter in such imaging.

By way of illustration of the lengthened imaging time windows which may be achieved using this embodiment, it has been found that harmonic imaging of a dog heart at 1.5 MHz produced useful results immediately after administration of a contrast agent comprising phosphatidylserine-stabilised perfluorobutane microbubbles.

Contrast agents useful in this embodiment of the invention include gas microbubbles encapsulated by

- 9 -

flexible membranes such that they readily undergo oscillations under the influence of ultrasound energy. They may therefore, for example, comprise amphiphile-stabilised, e.g. phospholipid-stabilised gas microbubbles, for example as hereinbefore described. Again the use of negatively charged phospholipids such as phosphatidylserines, e.g. to stabilise fluorinated gases such as perfluorobutane, may be particularly advantageous.

Alternatively the contrast agent microbubbles may be less flexibly encapsulated, e.g. by stabilised protein shells, where the encapsulating material is capable of transiently softening and becoming more elastic under the influence of ultrasound energy, thereby permitting volume oscillation.

It may be advantageous during imaging in accordance with the method of the invention, especially in cardiac imaging, to induce pharmacological stress in the subject. As is well known, such stress may enhance the distinction between normally perfused healthy tissue, e.g. of the myocardium, and tissue regions supplied by stenotic arteries. Thus healthy tissue undergoes vasodilatation and increased blood flow, and may therefore exhibit significantly increased contrast echo. Blood flow in underperfused tissue supplied by a stenotic artery, on the other hand, is substantially unchanged as a result of the capacity for arteriolar vasodilatation already being exhausted by inherent autoregulation seeking to increase the restricted blood flow.

Such pharmacological stress is conveniently induced by administration, e.g. by injection, of a vasodilator, preferably while imaging is being performed during the recirculating phase.

Representative examples of vasodilators which may be used include adenosine, dipyridamole, nitroglycerine, isosorbide mononitrate, prazosin, doxazosin, hydralazine, dihydralazine, sodium nitroprusside,

- 10 -

pentoxifylline, amelodipine, felodipine, isradipine, nifedipine, nimodipine, verapamil, diltiazem and nitric oxide. Stress-inducing agents such as arbutamine and dobutamine, which have a secondary vasodilatation-

5 inducing effect as a result of their metabolism-increasing effects, may similarly be used. Use of adenosine is particularly preferred since it is an endogenous substance and has a rapid but short-lived vasodilating effect. This latter property is  
10 confirmed by the fact that it has a blood pool half-life of only a few seconds; possible discomfort to patients during vasodilatation is therefore minimised.

Vasodilatation induced by adenosine will be most intense in the heart since the drug will tend to reach more  
15 distal tissues in less than pharmacologically active concentrations; it is therefore the vasodilator of choice in echocardiographic applications of this embodiment of the invention.

The following non-limitative Examples serve to  
20 illustrate the invention.

- 11 -

Example 1Cardiac imaging in a dog

5 An ultrasound contrast agent prepared as in Example 2(b)  
of WO-A-9729783 was injected intravenously into an  
anaesthetised dog as an intravenous bolus at dose levels  
corresponding to 1, 9 and 30 times the normal dose for  
imaging of the first-pass bolus effect, i.e. at doses  
10 corresponding to 0.03, 0.27 and 0.9  $\mu$ l of gas per kg  
body weight of the dog. The myocardium was imaged with  
an ATL HDI-3000 scanner equipped with a P3-5 transducer,  
operating in harmonic mode with a transmitted frequency  
of 2.1 MHz and a received frequency of 4.2 MHz. One  
15 image was recorded in each end-systole, using ECG  
gating. The useful imaging time windows for the  
different doses were respectively found to be 45 seconds,  
7 minutes and in excess of 45 minutes.

20 Example 2Cardiac imaging in a human

An ultrasound contrast agent prepared as in Example 2(b)  
25 of WO-A-9729783 is injected intravenously into a patient  
with a known left anterior descending coronary artery  
stenosis, as an intravenous bolus of 0.15  $\mu$ l of gas per  
kg body weight of the patient. This corresponds to 5  
times the normal dose for imaging of the first-pass  
30 bolus effect. The heart is imaged with a Hewlett  
Packard Sonos 2500 scanner operating in second harmonic  
mode with a transmitted frequency of 1.8 MHz, with the  
transducer in the parasternal short axis position. One  
end-systolic image is recorded every second heartbeat.  
35 After 5 minutes, still in the useful imaging time  
window, an infusion of adenosine is started at a rate of  
140  $\mu$ g/kg/minute. Some 30 seconds later, an increase in  
regional contrast echo intensity is seen in that part of

- 12 -

the myocardium supplied by normal arterial branches; the area supplied by the stenotic artery does not show such an increase.

5     Example 3

Imaging at lower frequencies

10     In a similar procedure to that described in Example 1, using the same brand of scanner and settings, imaging was performed using either a P3-2 transducer transmitting at 1.8 MHz or a P5-3 transducer transmitting at 2.1 MHz. The contrast agent was repeatedly injected at a dose level corresponding to  
15     0.03  $\mu$ l of gas per kg body weight of the dog. Apparent contrast enhancement of the myocardium was more intense with the P3-2 transducer, and ultrasound signal attenuation in the blood-filled left ventricle during peak bolus passage was observed to be less with this  
20     transducer. Additionally, the duration of adequate contrast effect after the initial phase of ventricular attenuation was greater using the P3-2 transducer.

- 13 -

Claims:

1. A method of ultrasound imaging which comprises  
(i) administering an ultrasound contrast agent  
5 comprising stabilised dispersion of gas microbubbles in  
an injectable carrier liquid to the vascular system of a  
subject in an amount which is physiologically tolerable  
and sufficient to generate contrast enhancement within  
blood in a recirculating phase following admixture of  
10 the agent with the blood pool; and  
(ii) generating an ultrasound image of at least a part  
of the vascular system of said subject during said  
recirculating phase.
- 15 2. A method as claimed in claim 1 wherein the contrast  
agent comprises gas microbubbles stabilised at the gas-  
carrier liquid interfaces by monolayers of amphiphilic  
material.
- 20 3. A method as claimed in claim 2 wherein said  
amphiphilic material comprises at least one  
phospholipid.
- 25 4. A method as claimed in claim 3 wherein said  
amphiphilic material consists essentially of  
phospholipid predominantly comprising molecules which  
individually have an overall net charge.
- 30 5. A method as claimed in claim 4 wherein  
substantially all of the phospholipid consists of  
molecules which individually have an overall net  
negative charge.
- 35 6. A method as claimed in claim 5 wherein one or more  
phosphatidylserines constitute at least 70% of the  
phospholipid.
7. A method as claimed in any of the preceding claims

- 14 -

wherein the gas microbubbles comprise sulphur hexafluoride or a perfluorinated low molecular weight hydrocarbon.

5      8.    A method as claimed in claim 7 wherein the perfluorinated low molecular weight hydrocarbon is perfluorobutane.

10     9.    A method as claimed in any of the preceding claims wherein an imaging frequency of 2 MHz or less is transmitted.

15     10.   A method as claimed in any of claims 1 to 8 wherein in step (ii) the ultrasound image is generated using a non-linear imaging technique.

20     11.   A method as claimed in claim 10 wherein the ultrasound image is generated by second harmonic imaging.

25     12.   A method as claimed in claim 10 or claim 11 wherein the contrast agent comprises gas microbubbles stabilised at the gas-carrier liquid interfaces by monolayers consisting essentially of phospholipid which predominantly comprises molecules which individually have an overall net charge, and said contrast agent is administered in a dose corresponding to 2-10  $\mu$ g of phospholipid per kg body weight of the subject.

30     13.   A method as claimed in any of claims 10 to 12 wherein in step (ii) the ultrasound image is generated using a transmit frequency below the mean resonance frequency of the gas microbubbles.

35     14.   A method as claimed in any of claims 10 to 12 wherein in step (ii) the ultrasound image is generated using a transmit frequency of 2 MHz or less.



- 15 -

15. A method as claimed in claim 14 wherein the transmit frequency is about 1.5 MHz.

5 16. A method as claimed in any of the preceding claims wherein pharmacological stress is induced in the subject during the ultrasound imaging.

10 17. A method as claimed in claim 16 wherein pharmacological stress is induced by administration of a vasodilator to the subject.

18. A method as claimed in claim 17 wherein said vasodilator is adenosine.

15 19. A method as claimed in claim 17 or claim 18 wherein the vasodilator is injected into the subject during ultrasound imaging in the recirculating phase.

20 20. Use of stabilised gas microbubbles in the manufacture of an ultrasound contrast agent for application in a method as defined in any of the preceding claims.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/02481

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K49/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 97 44067 A (ANDARIS LTD ; JOHNSON RICHARD ALAN (GB); WOUW PAULUS ANTONIUS V D ( ) 27 November 1997 see page 27, line 19 - page 28, line 9; claims 1-4	1
P,X	WO 97 29783 A (MARSDEN JOHN CHRISTOPHER ;BRAENDEN JORUN (NO); DUGSTAD HARALD (NO)) 21 August 1997 cited in the application see page 12, line 10-14; claims 1-79; examples 1-3	1-15
P,X	WO 98 17324 A (MARSDEN JOHN CHRISTOPHER ;ERIKSEN MORTEN (NO); OESTENSEN JONNY (NO) 30 April 1998 see claims 22-29	16-19
	-/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

9 December 1998

Date of mailing of the international search report

29/12/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Veronese, A

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/02481

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 26746 A (ALLIANCE PHARMA) 6 September 1996	1-15
Y	see page 5, line 18-26 see page 6, line 5-19; claims; examples 1-10	1-15
Y	WO 94 08627 A (DELTA BIOTECHNOLOGY LTD ;SUTTON ANDREW DEREK (GB); JOHNSON RICHARD) 28 April 1994 see page 17, line 30 - page 18, line 24 see page 20, line 16-21; claim 11	1-15
Y	EP 0 324 938 A (MOLECULAR BIOSYSTEMS INC) 26 July 1989 see page 3, line 4-16; claim 1	1-15
Y	MALCOM ROWLAND AND AL.: "Clinical Pharmacokinetics: concepts and applications", LEA AND FEBIGER , PHILADELPHIA XP002087081 * See figure 12-9, pag. 166 * see page 155 - page 172	1-15
Y	WO 94 09829 A (SINT SA) 11 May 1994 see the whole document	1-15
X	PORTER T.R.: "Detection of myocardial perfusion in multiple echocardiographic windows with one intravenous injection of microbubbles using transient response second harmonic imaging" JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 29, no. 4, 15 March 1997, pages 791-799, XP002087079 see the whole document	13-19
X	PORTER T.R. ET AL.: "Detection of regional perfusion abnormalities during adenosine stress echocardiography with intravenous perfluorocarbon-exposed sonicated dextrose albumin" AMERICAN HEART JOURNAL, vol. 132, 1996, pages 41-47, XP002087080 see the whole document	16-19

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB 98/02481

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim(s) 1-19  
is(are) directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/02481

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9744067 A	27-11-1997	AU 2909597 A	09-12-1997
WO 9729783 A	21-08-1997	AU 1805197 A	02-09-1997
		AU 1884797 A	02-09-1997
		EP 0881915 A	09-12-1998
		WO 9729782 A	21-08-1997
		NO 983420 A	24-07-1998
WO 9817324 A	30-04-1998	AU 4714797 A	15-05-1998
WO 9626746 A	06-09-1996	US 5798091 A	25-08-1998
		AU 4922196 A	18-09-1996
		CA 2212113 A	06-09-1996
		CN 1182373 A	20-05-1998
		EP 0812214 A	17-12-1997
		FI 973496 A	26-08-1997
		NO 973489 A	27-08-1997
		PL 321952 A	05-01-1998
WO 9408627 A	28-04-1994	EP 0663840 A	26-07-1995
		GB 2286122 A,B	09-08-1995
		GB 2302649 A,B	29-01-1997
		GB 2302650 A,B	29-01-1997
		JP 8505366 T	11-06-1996
EP 0324938 A	26-07-1989	US 4844882 A	04-07-1989
		CA 1325590 A	28-12-1993
		CN 1035774 A,B	27-09-1989
		DE 3885730 D	23-12-1993
		DE 3885730 T	10-03-1994
		DK 721688 A	30-06-1989
		FI 886016 A,B,	30-06-1989
		IE 61591 B	16-11-1994
		JP 1203337 A	16-08-1989
		JP 6062445 B	17-08-1994
		KR 9605709 B	01-05-1996
		NO 176826 B	27-02-1995
WO 9409829 A	11-05-1994	AT 146972 T	15-01-1997
		AU 2618197 A	18-12-1997
		AU 681812 B	04-09-1997
		AU 3431795 A	04-01-1996
		AU 666238 B	01-02-1996
		AU 5336294 A	24-05-1994
		CA 2125027 A	11-05-1994
		CN 1088456 A	29-06-1994
		DE 69307124 D	13-02-1997
		DE 69307124 T	17-07-1997
		DK 619743 T	20-01-1997
		EP 0619743 A	19-10-1994
		ES 2097548 T	01-04-1997
		FI 943167 A	01-07-1994
		GR 3022826 T	30-06-1997
		HU 74561 A	28-01-1997
		IL 107453 A	04-01-1998
		JP 7503254 T	06-04-1995
		NO 942476 A	30-06-1994
		NZ 257115 A	24-06-1997

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/02481

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9409829 A		NZ 280615 A	24-02-1997
		US 5445813 A	29-08-1995
		US 5597549 A	28-01-1997
		US 5686060 A	11-11-1997
		ZA 9308117 A	23-06-1994
<hr/>			